UBC Medical Indonesia Tbk. vs Prodia Diagnostic Line Tbk — how do they compare? UBC Medical Indonesia Tbk. trades at Rp174 (market cap 691.25B, 635.5K 24h volume), while Prodia Diagnostic Line Tbk trades at Rp236 (market cap 428.75B, 13.83M 24h volume). The key difference: UBC Medical Indonesia Tbk. is the larger of the two by market cap, and Prodia Diagnostic Line Tbk is more actively traded (13.83M versus 635.5K). Which is the better fit depends on your goals.
| LABS | PRDL | |
|---|---|---|
Market Cap | 691.25B | 428.75B |
Volume | 635.5K | 13.83M |
Lot | 6.36K | 138.27K |
Turnover | 110.15M | 3.27B |
Average Price | 173.33 | 236.62 |
Value | 110.15M | 3.27B |
Indicative Equilibrium Price | 174 | 236 |
Indicative Equilibrium Volume | 50 | 1.74K |
Trailing returns across standard periods
Latest headlines on both assets
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →